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Abstract
We have previously shown that in successful pregnancies increased arginase activity is a mechanism that contributes to the
suppression of the maternal immune system. We identified the main type of arginase-expressing cells as a population of
activated low-density granulocytes (LDGs) in peripheral blood mononuclear cells and in term placentae. In the present
study, we analyzed the phenotype of LDGs and compared it to the phenotype of normal density granulocytes (NDGs) in
maternal peripheral blood, placental biopsies and cord blood. Our data reveal that only LDGs but no NDGs could be
detected in placental biopsies. Phenotypically, NDGs and LDGs from both maternal and cord blood expressed different
levels of maturation, activation and degranulation markers. NDGs from the maternal and cord blood were phenotypically
similar, while maternal, cord and placental LDGs showed different expression levels of CD66b. LDGs present in cord blood
expressed higher levels of arginase compared to maternal and placental LDGs. In summary, our results show that in
maternal and cord blood, two phenotypically different populations of neutrophils can be identified, whereas in term
placentae, only activated neutrophils are present.
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Introduction
Transient modulation of innate and adaptive maternal immu-
nity during pregnancy contributes to the creation of an
immunosuppressive state allowing implantation and growth of
the fetus. Although there is bidirectional communication and
migration of fetal and maternal cells throughout pregnancy the
paternal antigens expressed by the fetus are not attacked and
rejected by the maternal immune system [1]. It is generally
accepted that in successful healthy pregnancies multiple mecha-
nisms provided by both the mother and the fetus contribute to the
development and maintenance of immune tolerance and immune
privilege [2]. In normal pregnancies there is an increased systemic
inflammation, enhanced number of polymorphonuclear cells
(PMN), a low Th1/Th2 balance, a decrease in peripheral NK
cells, and an increased number of regulatory T cells [3,4,5].
Although major progress has been made in the understanding of
immune mechanisms that prevent rejection of the fetus, the
generation of this immunosuppressive state is not fully elucidated
[6].
Indoleamine 2,3 dioxygenase (IDO), a tryptophan-catabolizing
enzyme expressed by both the maternal decidua and fetal
trophoblast and catabolites of the tryptophan metabolism such
as kynurenine and picolinic acid can inhibit lymphocyte activation
and have been shown to contribute to the Th2 bias and to
tolerance induction and maintenance in pregnancy [7].
We previously showed that another amino acid catabolizing
enzyme, arginase, is upregulated in term placentae as well as in the
peripheral blood at parturition and contributes to suppression of
maternal immune responses in healthy pregnancies [8]. Two
isoforms of arginase exist, arginase I and II, which both hydrolyze
the same substrate, the amino acid L-arginine, to ornithine and
urea. They differ in cellular and subcellular expression and
regulation. Both arginase isoforms are expressed in the human
placenta [9] and increased enzymatic activity of arginase results in
elevated substrate consumption and decreased L-arginine in the
extracellular fluid. L-arginine is essential for T cell activation and
the generation of nitric oxide (NO) [10,11]. Indeed, reduction of
extracellular L-arginine by the enzymatic activity of arginase
impairs maternal T cell responses; thus, arginase-induced L-
arginine deprivation is one of the pathways ensuring T cell
hyporesponsiveness and immune privilege at the feto-maternal
interphase [8]. We have previously identified the phenotype of
arginase-expressing cells in maternal blood and placentae as low-
density granulocytes (LDGs) that co-purify with PBMCs following
density gradient centrifugation. This difference in density distin-
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guishes this population from the remaining granulocytes that co-
purify with the erythrocyte fraction following density gradient
centrifugation and thus have been named normal-density granu-
locytes (NDGs).
In the present study we analyzed the phenotype and frequency
of normal and low density granulocytes obtained from maternal
peripheral blood, placental biopsies and cord blood.
Materials and Methods
Ethics Statement
This study protocol was approved by the NHS NRES
Committee South Central Oxford A (REC reference 12/SC/
0721; IRAS project ID 1181020).
Subjects and Samples
All individuals gave written, informed consent before partici-
pation. Pregnant women (n= 7; mean age 34years, mean BMI 26)
were recruited at the time of elective caesarean section; the mean
gestational age at delivery was 38 weeks and 6 days. Exclusion
criteria included any major complication of pregnancy or
intercurrent illness, such as pre-eclampsia, pre- or post-term labor
(,37 weeks or .42 weeks), intra-uterine growth retardation, viral,
bacterial or parasitic infections.
Ten ml of maternal peripheral blood and of cord blood were
collected in EDTA tubes and PBMCs were isolated by density
gradient centrifugation on Histopaque 1077 (Sigma). Neutrophils
were isolated from the erythrocyte fraction by dextran sulphate
sedimentation [12].
Placentae were harvested directly after parturition and up to
five small biopsies were taken through the full thickness of the
placenta. Single cell suspensions were obtained by homogenizing
biopsies in PBS on cell dissociation sieves and purified from debris
by Histopaque 1077 density gradient centrifugation. The placental
cells (PlaC) obtained were washed and resuspended in PBS. All
experiments were performed on fresh cells, immediately after
processing.
Flow Cytometry
The following antibodies purchased from Biolegend were used:
CD66bFITC (involved in respiratory burst, adhesion molecule,
present in the membrane of specific granules); CD15PE (involved
in cell-cell interactions, phagocytosis, stimulation of degranulation,
Figure 1. Phenotypic analysis of LDGs and NDGs. LDGs and NDGs were isolated as described in materials and methods (n = 7) and the
expression levels of arginase, CD66b, CD15, CD63, CD33 and CD16 were determined by flow cytometry. Statistical significance was determined by a
two-tailed Mann-Whitney test. Box = interquartile range and median; whiskers = range.
doi:10.1371/journal.pone.0085696.g001
Table 1. Expression levels of arginase and phenotypic
markers of NDGs and LDGs in cord blood.
CORD BLOOD NDGs LDGs p values
Arginase 1 13126249 860642 0.0047
CD66b 658861153 1460562414 0.0023
CD15 1089661664 4472066046 0.0023
CD63 30046880 682061017 0.0513
CD33 8516216 18516296 0.0159
CD16 60066871 3646136 0.0043
NDGs and LDGs were isolated from cord blood (n = 7) as described in materials
and methods. Expression levels (MFI) of phenotypic markers were determined
by flow cytometry. Statistical significance was determined by a two-tailed
Mann-Whitney test.
doi:10.1371/journal.pone.0085696.t001
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and respiratory burst); CD63PE-Cy7 (marker for release of
azurophilic granules); CD33PE-Cy5 (marker of immature neutro-
phils, adhesion molecule); CD16AF700 (Marker of mature granu-
locytes, involved in degranulation). In addition, Zenon Pacific blue
conjugated Arginase-1 (Hycult Biotechnology/Invitrogen) was
used to detect intracellular arginase 1. The Live/Dead Fixable
Near-IR dye (Invitrogen) was used to distinguish live and dead
cells.
Cells isolated from cord blood, PlaCs and PBMC were washed
and incubated with 20 ml FcR blocking reagent for 5 minutes and
stained for 20 minutes with cell surface markers at room
temperature. Cells were washed with FACS medium and fixed
with cold 4% formaldehyde on ice for 20 minutes.
For intracellular staining, 0.5% saponin was used to permea-
bilize the cells for 20 minutes at room temperature and then
stained with arginase 1 Pacific blue conjugated antibody for a
further 20 minutes. The cells were washed and analyzed
immediately with an LSRII flow cytometer (BD Bioscience). The
results were analyzed using FlowJo v9.6.2 (Tree Star, Ashland,
OR).
Statistical Analyses
Data were evaluated for statistical differences using a two-tailed
Mann-Whitney test and a Kruskal-Wallis test when appropriate
(GraphPad PRISM version 5); differences were considered
significant at p,0.05. Results are expressed as median 6 SEM.
Results
Phenotype and Frequency of Neutrophil Subpopulations
in Maternal Blood, Cord Blood and Term Placentae
We have previously shown that the cells expressing arginase in
the PBMCs and placentae of pregnant women are a population of
low-density granulocytes (LDGs) that co-purify with PBMCs
following density gradient centrifugation [8,13]. This difference
in density distinguishes this population from the remaining
granulocytes that co-purify with the erythocyte fraction following
density gradient centrifugation and thus have been named normal-
density granulocytes (NDGs).
Here we first determined whether both neutrophil subpopula-
tions, LDGs and NDGs, were detectable in the maternal and cord
blood and in the term placentae. Whereas both LDGs and NDGs
were isolated from maternal and cord blood, NDGs could not be
isolated from term placentae despite using different methods such
as Histopaque 1119 density gradient centrifugation or isolation by
dextran sedimentation from the erythrocyte fraction of Histopaque
1077 gradients.
First we compared the expression levels of arginase, activation
and maturation markers by LDGs and NDGs in maternal and
cord blood since we had previously shown that the expression
levels of arginase, CD15, CD16, CD33, CD63 and CD66b are
modulated on LDGs [12]. The expression levels on placental
LDGs is shown throughout Figure 1 (after the broken line) for
comparison. As shown in Figure 1 and Tables 1 and 2, NDGs
present in both maternal and cord blood express significantly more
arginase than LDGs; the reduced expression of CD63 on NDGs is
in agreement with the higher arginase levels and indicate that
these cells are less activated and have not degranulated arginase-
containing CD63+ azurophilic granules. The lower arginase
expression by LDGs in cord blood, maternal blood and in the
placenta corresponds with increased CD63 expression and
indicate that these cells had been activated and had degranulated
Table 2. Expression levels of arginase and phenotypic
markers of NDGs and LDGs in maternal peripheral blood.
MATERNAL BLOOD NDGs LDGs p values
Arginase 1 14526216 906669 0.0262
CD66b 783661021 1768261072 0.0006
CD15 68206914 2120763198 0.0006
CD63 42276505 851561259 0.0350
CD33 11546198 26586378 0.0043
CD16 46376531 247686 0.0012
NDGs and LDGs were isolated from maternal blood (n = 7) as described in
materials and methods. Expression levels (MFI) of phenotypic markers were
determined by flow cytometry. Statistical significance was determined by a
two-tailed Mann-Whitney test.
doi:10.1371/journal.pone.0085696.t002
Figure 2. Comparison of the phenotype of LDGs in neonate
and maternal blood and placentae. LDGs were isolated as
described in materials and methods (n = 7) and the expression levels
of CD66b was determined by flow cytometry. Statistical significance
was determined by a kruskal-Wallis test. Box = interquartile range and
median; whiskers = range.
doi:10.1371/journal.pone.0085696.g002
Table 3. Comparison of expression levels of arginase and
phenotypic markers of LDGs in placentae, cord and maternal
blood.
LDGs Cord blood Maternal blood Placentae p values
Arginase 1 860642 906669 10976118 0.2801
CD66b 1460562414 1768261072 1281861499 0.0233
CD15 4472066046 2120763198 2147467353 0.1961
CD63 682061017 851561259 673861686 0.6977
CD33 18516296 26586378 21996220 0.4565
CD16 3646136 247686 347261438 0.2368
LDGs were isolated from maternal and cord blood (n = 7) as described in
materials and methods. Expression levels (MFI) of phenotypic markers were
determined by flow cytometry. Statistical significance was determined by a
two-tailed Mann-Whitney test.
doi:10.1371/journal.pone.0085696.t003
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arginase+ azurophilic granules. Furthermore, the increased
expression of CD66b by LDGs from all three sources also
indicates that LDGs are more activated than NDGs.
The expression levels CD33, a marker of immature neutrophils,
were significantly higher in LDGs present in placentae, maternal
and cord blood and indicate that LDGs might be a heterogenous
population containing both mature and immature neutrophils.
CD15 and CD16 are expressed by mature neutrophils and the
increased expression of CD15 on LDGs from the three
compartments analyzed could be due to upregulation of this
molecule in response to activation and degranulation [14].
In conclusion, these results show that LDGs are phenotypically
different from NDGs in both maternal and cord blood.
Next, we determined whether there are phenotypic differences
in LDGs from the three compartments. As shown in Figure 1 and
Table 3, the phenotype of LDGs in placentae, maternal and cord
blood was similar, except for the expression levels of CD66b
(Figure 2), which was lower in the placentae, as compared to
maternal and cord blood. Results in Table 4 show that the
phenotype of NDGs is similar in maternal and cord blood;
however, NDG could not be isolated from placentae.
Finally, we determined the frequency of LDGs and our results
show that there are significantly more LDGs in cord blood as
compared to the placentae or maternal blood (Figure 3 and
Table 5).
Discussion
Modulation of both innate and adaptive immune responses is
crucial in successful pregnancy since the symbiosis between
mother and fetus is not due to immunological ignorance but
rather to suppression of maternal immune responses. Arginase-
mediated L-arginine catabolism is a well-established mechanism of
T cell suppression [10,15,16]. We showed previously that arginase
activity is significantly increased in the placenta and in maternal
blood and that arginase-induced L-arginine catabolism is one of
the pathways contributing to suppression of maternal T cells
responses in healthy human pregnancies [8]. Furthermore, we
demonstrated recently that arginase activity and L-arginine levels
return to physiological levels after birth [17].
In the present study we further characterized the phenotype of
LDGs and compared it to normal density granulocytes (NDGs)
isolated from placental biopsies, maternal and cord blood. At
parturition both subsets of neutrophils are present in peripheral
maternal blood and in cord blood, however, from term placentae
only LDGs could be isolated and despite using different methods it
was not possible to isolate normal density granulocytes from term
placentae. After density gradient centrifugation of blood, NDGs
sediment with erythrocytes whereas LDGs co-purify with the
PBMC fraction suggesting that their density is lower [13]. They
also differ phenotypically: NDGs from maternal and cord blood
express significantly higher cell surface levels of CD16 and
significantly more intracellular arginase as compared to LDGs.
The cell surface levels of CD63 were significantly lower in NDGs
than in LDGs. In human neutrophils arginase is contained in
azurophilic [18] and gelatinous granules and upregulation of
CD63 coincides with the release of azurophilic granules [19].
Thus, our results showing that CD63 is increased in LDGs suggest
that these cells have been activated and have degranulated.
Furthermore, increased expression levels of CD15 have also been
associated with degranulation [14]. Indeed, the increased cell
surface expression of CD66b, CD15, and CD63 on LDGs support
this conclusion.
The frequency of LDGs was highest in cord blood, however, the
phenotype of LDGs in maternal blood, term placentae and cord
blood was similar and the phenotype of NDGs in maternal and
Table 4. Comparison of expression levels of arginase and




blood Placentae p values
Arginase 1 13126249 14526216 None recovered 0.9452
CD66b 658861153 783661021 None recovered 0.6282
CD15 1089661664 68206914 None recovered 0.5338
CD63 30046880 42276505 None recovered 0.3095
CD33 8516216 11546198 None recovered 0.2468
CD16 60066871 46376531 None recovered 0.2525
NDGs were isolated from maternal and cord blood (n = 7) as described in
materials and methods. Expression levels (MFI) of phenotypic markers were
determined by flow cytometry. Statistical significance was determined by a
two-tailed Mann-Whitney test.
doi:10.1371/journal.pone.0085696.t004
Figure 3. Percentage of LDGs in neonatal and maternal blood
and placentae. LDGs were isolated as described in materials and
methods (n = 7) and the percentage of CD15+ arginase+ cells was
determined by flow cytometry. The percentage of LDGs present in the
peripheral blood of healthy controls was 0.2460.3 [12] Statistical
significance was determined by a kruskal-Wallis test. Box = interquartile
range and median; whiskers = range.
doi:10.1371/journal.pone.0085696.g003
Table 5. Percent of Arginase1+CD15+ LDGs present in




blood placentae p valueip
Arginase 1 5.6661.24 1.72360.95 2.1460.53 0.0237
LDGs were isolated from maternal and cord blood and placentae (n = 7) as
described in materials and methods. The percentage of CD15+ arginase+ cells
was determined by flow cytometry. Statistical significance was determined by a
Kruskal-Wallis test.
doi:10.1371/journal.pone.0085696.t005
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cord blood was also not significantly different.
CD15+ neutrophils in the PBMC fraction have not only been
observed in pregnancy (present study and [8]. It was also reported
in a range of conditions including HIV [12], visceral leishmaniasis
[20], cancer [15,16,21], trauma [22], and systemic lupus
erythromatosus [23]. All of these conditions are frequently
accompanied by various degrees of immune suppression.
Pregnancy has been associated with a shift in Th1/Th2 balance,
reduced type 1responsiveness [3,4] and enhanced innate immu-
nity. Indeed, the number of neutrophils increases in pregnancy
and these cells undergo functional and metabolic changes
[24,25,26]. Delayed apoptosis of neutrophils in normal pregnancy
promotes inflammation to persist and may contribute to pregnan-
cy-associated neutrophilia and pregnancy-induced inflammatory
changes in neutrophils in the peripheral blood are akin to those of
sepsis [27]. The function of neutrophils in pregnancy has to be
very tightly controlled since enhanced inflammatory responses
have been linked to pregnancy complications such as preeclamp-
sia.
Neutrophils home to inflammatory sites, they can phagocytose
pathogens, degranulate and release web-like structures, the
neutrophil extracellular traps (NETs) that are implicated in
inflammation and immunity [28]. Placental micro-debris has been
shown to activate neutrophils and induce the formation of NETs
in a dose-dependent manner [29]. NETs have been suggested to
contribute to placental hypoxia in patients with preeclampsia [30];
however, the interplay between micro-debris, neutrophil activation
and NETs in successful human pregnancies remains to be
determined.
Arginase-mediated L-arginine catabolism is not only impacting
on maternal immune responses [8]; amino acids such as L-
arginine are also important for the developing fetus. Fetal growth
is critically dependent on placental nutrient transport; specialized
transporters can pass them to the fetus [31]. Placental amino-acid
uptake takes place on the microvillous membrane of the
syncytiotrophoblast and the efflux to the fetus is mediated by
transporters on the basal membrane. The mammalian target of
rapamycin (mTOR) pathway in the placenta regulates amino acid
transporters such as L-arginine, and it has been proposed that the
placental mTOR pathway constitutes a link between maternal
nutrients and fetal growth [32].
The signals resulting in activation, degranulation of neutrophils
and their development into LDGs in pregnancy remain to be
determined and further work is required to identify the pathways
leading to the generation of LDGs.
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